SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

SHIBs recent price uptick and attempts to break through resistance are driving speculation about a renewed meme-coin rally, with traders watching for a breakout. The community is split between accumulation and bullish hopes for a pump and frustration over prolonged sideways trading, weak utility, and limited token burns.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is drawing attention as shares break to fresh highs, alongside positive drug developments including FDA approval of Juvmo for Parkinsons disease and encouraging Phase 3 lymphoma results with Genmab. Traders are broadly bullish on the momentum, though some question whether the breakout can hold.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

FET is drawing attention amid a rebound and renewed rotation into AI-related crypto tokens, with traders focusing on Fetch.ais autonomous-agent and ASI ecosystem. Bulls point to improving momentum and accumulation, while skeptics cite resistance levels, past underperformance, and dependence on broader crypto conditions.

Injective is an interoperable Layer 1 blockchain designed for DeFi applications. It provides developers with on-chain financial infrastructure modules to build dApps such as decentralized exchanges, prediction markets, and lending protocols. Its decentralized cross-chain bridging infrastructure offers compatibility with most blockchains, including EVM chains like Ethereum and non-EVM chains like Solana.

Injective

Injectives live Supply Squeeze governance proposal is drawing attention, with traders focused on the possibility that approval would double INJs deflation rate; bullish posts also point to staking, burns and the chains RWA and finance activity. Sentiment is sharply divided between accumulation and long-term optimism and skepticism about INJs prolonged weakness, while some users complain that repeated Nonja promotion is cluttering discussion.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is drawing attention for its strong rally and repeated 52-week highs, with bullish traders pointing to momentum and demand for its data-security platform. Others argue the stock looks expensive and cite insider selling, managements guidance, and lagging performance versus cybersecurity peers as reasons for caution.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

COMP is drawing attention on bullish breakout setups, with traders citing chart patterns and its capped token supply. Optimism about Compounds institutional-market push and V4 roadmap is tempered by complaints that the token has lagged other crypto assets.

Air Canada engages in the provision of airline transportation services. Its services cover full-service airline, scheduled passenger and cargo services, serving more than two hundred airports on six continents. It operates through the following geographical segments: Canada, U.S. Transborder, Atlantic, Pacific, and Other. The company was founded on April 11, 1936 and is headquartered in Saint-Laurent, Canada.

Air Canada Inc. - Ordinary Shares (Voting and Variable Voting)

Air Canada Inc.

Air Canada is drawing attention after a sharp selloff, with traders debating whether shares not accepted in the substantial issuer bid are adding selling pressure; that explanation remains speculation. Bearish posts also cite elevated fuel costs and earnings risk, while bulls point to potential buybacks and argue that short-selling is worsening the decline.

Grayscale Ethereum Trust (ETH) operates as open-end investment company. Its investment objective is for the shares to reflect the value of ETH held by the trust. The company was founded on December 13, 2017 and is headquartered in Stamford, CT.

Grayscale Ethereum Staking Mini ETF - Common units of fractional undivided beneficial interest

Grayscale Ethereum Mini Trust

Ethereums sharp rebound and breakout have driven attention, with traders citing institutional adoption, ETF flows, and crypto-regulation optimism as supportive themes. Bullish momentum is contested by concerns about thin volume, pullbacks, and whether gains can hold.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow shares are under pressure amid investor frustration over repeated revenue-guidance misses and VEVYEs weak monetization, including pricing and gross-to-net concerns. Long-term bulls view the pullback and insider buying as an opportunity, while skeptics want cleaner execution before trusting the growth outlook.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Power and Energy, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Power and Energy segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925, and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillar is drawing attention after a sharp pullback amid an FTC/USDA inquiry into agricultural-equipment practices and a broker downgrade. Traders debate whether the selloff is an overreaction because the inquiry is industry-wide and CATs business is weighted toward construction, mining and power; dip buyers are looking for a rebound while bearish voices point to continued weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Indian companies invest USD 20.5 billion in US, pharma tops

… Embassy & Consulates in India. The pharmaceutical sector accounted for the vast majority … ;s Laboratories Ltd, Glenmark Pharmaceuticals Ltd, Granules India Ltd, Jubilant … Group, Lupin Limited, Piramal Pharma Ltd., and Zydus Lifesciences Limited …

Brief India: Sharda Cropchem - Continuing Momentum Despite Geopolitical Tantrums and more

In this briefing: Sharda Cropchem - Continuing Momentum Despite Geopolitical Tantrums Primer: Anthem Biosciences (1234D IN) - Apr 2026 Amagi Media Labs: Taking Media Companies to the Cloud Universe Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins 1. Sharda Cropchem - Continuing Momentum Despite Geopolitical Tantrums Sharda Cropchem is an asset-light agrochemical supplier that sources products mainly from China and India, sells globally, and builds competitive advantage through extensive regulatory product registrations instead of manufacturing capabilities. They invest heavily in product registrations, creating large pipeline that converts into revenue over time, driving strong cash flows funding growth internally, and supporting dividends despite high accounting amortization charges. Sharda’s massive registration pipeline and presence in regulated markets drive growth despite sourcing and forex risks.

Brief India: Primer: Anthem Biosciences (1234D IN) - Apr 2026 and more

In this briefing: Primer: Anthem Biosciences (1234D IN) - Apr 2026 Amagi Media Labs: Taking Media Companies to the Cloud Universe Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan 1. Primer: Anthem Biosciences (1234D IN) - Apr 2026 Anthem Biosciences is a fully integrated Contract Research, Development, and Manufacturing Organization (CRDMO) providing end-to-end services for small and large molecules to the global pharmaceutical and biotechnology sectors. The company has demonstrated a strong financial track record, with a 32% CAGR in operating revenue between FY23 and FY25, and boasts industry-leading EBITDA margins. Key growth drivers include its leadership in fermentation capacity in India, expertise in advanced therapeutic modalities like ADCs and RNAi, and a strategic focus on backward integration to reduce reliance on external suppliers.

Brief India: Amagi Media Labs: Taking Media Companies to the Cloud Universe and more

In this briefing: Amagi Media Labs: Taking Media Companies to the Cloud Universe Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan The Adani Group Clearance: Deconstructing the CCI Verdict and What It Means for the Conglomerate 1. Amagi Media Labs: Taking Media Companies to the Cloud Universe Amagi's unified cloud-based media infrastructure serves to digitise traditional media content and enable monetisation. Its two-way platform supports not just the content-owners but also distributors globally with varied content access By attracting both media companies and distributors, Amagi benefits from a content-driven flywheel effect, creating structural stickiness with 120+% NRR and 35–50% cost savings for broadcasters. Amagi has been a key enabler for broadcasting for live-events (FIFA, NFL) while its content library attracts small/new OTT platforms.

Brief Multi-Strategy: Approaches Aimed at Resolving “parent-Subsidiary Listings” in the Broad Sense Remain Effective and more

In this briefing: Approaches Aimed at Resolving “parent-Subsidiary Listings” in the Broad Sense Remain Effective Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) HEW: Rallying into the Void Japan Strategy Weekly Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins 1. Approaches Aimed at Resolving “parent-Subsidiary Listings” in the Broad Sense Remain Effective A common challenge faced by Japanese companies is inability to concentrate resources on businesses with high profit margins and growth potential, resulting in failure to successfully expand promising businesses overseas. Establishing and implementing clear criteria for deciding when to invest in or withdraw from businesses is essential for restructuring the business portfolio. The litmus test is eliminating parent-subsidiary dual listings. The Standard Market is likely to become the main battleground for efforts to resolve parent-subsidiary dual listings.In the Prime Market, increased approaches from activist investors targeting equity-method affiliates are inevitable. 2.

Brief Multi-Strategy: Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) and more

In this briefing: Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) HEW: Rallying into the Void Japan Strategy Weekly Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins The Stocks to Own in China – Vol. 39 1. Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Downstream oil products remain elevated, yet oil futures continue to soften. GCC states say that it will take years to rebuild and replace some infrastructure. The petrodollar has taken a hit as Gulf countries are selling less oil and emerging markets are forced to sell dollars to plug deficits caused by higher oil prices. The petroyuan is gaining traction as the Middle East conflict has rerouted some payments through the Chinese CIPS and mBridge networks. 2. HEW: Rallying into the Void No news was good enough news for risk assets to keep rallying, but even a benign end to the US-Iran war will not negate the inflation shock lifting policy rates. EA inflation recovered some of its downside surprise in its final March print, but the UK’s international stature can’t recover.

Brief India: Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) and more

In this briefing: Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan The Adani Group Clearance: Deconstructing the CCI Verdict and What It Means for the Conglomerate Primer: Cipla Ltd (CIPLA IN) - Apr 2026 1. Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Downstream oil products remain elevated, yet oil futures continue to soften. GCC states say that it will take years to rebuild and replace some infrastructure. The petrodollar has taken a hit as Gulf countries are selling less oil and emerging markets are forced to sell dollars to plug deficits caused by higher oil prices. The petroyuan is gaining traction as the Middle East conflict has rerouted some payments through the Chinese CIPS and mBridge networks. 2. Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins US Paracetamol prices jumped 24.6% MoM in March 2026 , driven by post-Lunar New Year Chinese supply pullback, Indian facility FDA alerts & surging para-aminophenol cost.

Brief Multi-Strategy: HEW: Rallying into the Void and more

In this briefing: HEW: Rallying into the Void Japan Strategy Weekly Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins The Stocks to Own in China – Vol. 39 CX Daily: ByteDance’s Billion-Yuan Bet on China’s First AI-Native Hospital? 1. HEW: Rallying into the Void No news was good enough news for risk assets to keep rallying, but even a benign end to the US-Iran war will not negate the inflation shock lifting policy rates. EA inflation recovered some of its downside surprise in its final March print, but the UK’s international stature can’t recover. It failed to defend its investing allies. Next week is packed with news for the UK, where the rise in its inflation data is our highlight, with its labour market and global flash PMIs other notable releases. 2. Japan Strategy Weekly Japanese equities posted a modest gain this week, with the Topix Index rising +0.6% and extending its year-to-date advance to +10.3%. The move came against a supportive global backdrop, as U.S. markets rallied strongly— Nasdaq climbed ~4%—helping sustain risk appetite despite pockets of volatility.

Brief Multi-Strategy: Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins and more

In this briefing: Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins The Stocks to Own in China – Vol. 39 CX Daily: ByteDance’s Billion-Yuan Bet on China’s First AI-Native Hospital? The Adani Group Clearance: Deconstructing the CCI Verdict and What It Means for the Conglomerate Samsung Electronics - Pays Out Special Dividend & Consensus Likely to Raise DPS by 30%+ for 2026 1. Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins US Paracetamol prices jumped 24.6% MoM in March 2026 , driven by post-Lunar New Year Chinese supply pullback, Indian facility FDA alerts & surging para-aminophenol cost. Indian API-heavy players like Granules India, Aurobindo, Dr. Reddy's & IPCA face squeeze of input costs & restricted supply of exports , compressing EBITDA when the US pharma tariff threat looms. Integrated giants like Sun Pharma & Cipla have buffers; pure-play API and formulation players like Granules India are most exposed. This situation is worth tracking closely heading into FY26 earnings. 2.

Brief India: Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins and more

In this briefing: Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan The Adani Group Clearance: Deconstructing the CCI Verdict and What It Means for the Conglomerate Primer: Cipla Ltd (CIPLA IN) - Apr 2026 Primer: Indus Towers (INDUSTOW IN) - Apr 2026 1. Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins US Paracetamol prices jumped 24.6% MoM in March 2026 , driven by post-Lunar New Year Chinese supply pullback, Indian facility FDA alerts & surging para-aminophenol cost. Indian API-heavy players like Granules India, Aurobindo, Dr. Reddy's & IPCA face squeeze of input costs & restricted supply of exports , compressing EBITDA when the US pharma tariff threat looms. Integrated giants like Sun Pharma & Cipla have buffers; pure-play API and formulation players like Granules India are most exposed. This situation is worth tracking closely heading into FY26 earnings. 2. Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan Gold loans have overtaken home loans by origination value, reaching ~39% of retail disbursals as of December 2025, with the portfolio growing 4x since March 2022 to ~INR3.38 lakh crore.

Granules India Ltd. engages in the manufacturing and marketing of pharmaceutical products. It operates through the following business segments: Active Pharmaceutical Ingredient, Pharmaceutical Formulation Intermediates, and Finished Dosages. The company was founded by Krishna Prasad Chigurupati on March 18, 1991 and is headquartered in Hyderabad, India.

Current Price	814.00
Prev Close	814.00
Open	815.05
Dividend Yield	0.28%
50-Day Moving Average	857.84
Beta	-0.02
Avg. Volume	1.48M
PE Ratio	30.12

52-Week High	985.00
52-Week Low	529.85
Market Capitalization	202B
EPS (Annual)	24.47
Price to Book	3.97
Revenue Per Employee	8.23M

Feed

News

Sentiment

Fundamentals

Info

GRANULES.NSE Fundamentals